The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
Official Title: A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy
Study ID: NCT03769506
Brief Summary: A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy
Detailed Description: The study will have an Experimental Arm and a Control Arm. Experimental Arm: Patients may receive repeated ASP-1929 PIT interventions for up to a maximum of 8 cycles within a period of up to 12 months after randomization until the patient has complete remission, progressive disease that is no longer amendable to study treatment, patient experiences intolerable side effects, or patient discontinues study treatment. Repeat ASP-1929 treatment cycles will be administered no less than 4 weeks from the previous ASP-1929 infusion. Control Arm: Patients may be treated with physician's choice standard of care until the patient has progressive disease, patient experiences intolerable side effects, discontinues study treatment, or chooses to withdraw.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of South Florida, Tampa, Florida, United States
Grady Health, Atlanta, Georgia, United States
University of Kentucky, Albert B. Chandler Medical Center, Lexington, Kentucky, United States
William Beaumont Hospital, Royal Oak, Michigan, United States
Thomas Jefferson University - Sidney Kimmel Medical College, Philadelphia, Pennsylvania, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Vanderbilt University, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
Kailash Cancer Hospital and Research Center, Vadodara, Gujarat, India
Cancer Institute (W.I.A), Chennai, Tamilnadu, India
Aichi Cancer Center, Nagoya-shi, Aichi, Japan
National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
Hokkaido University Hospital, Sapporo-shi, Hokkaido, Japan
Okayama University Hospital, Okayama-shi, Okayama, Japan
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
National Taiwan University Hospital, Zhongzheng, Taipei, Taiwan
China Medical University Hospital, Taichung, , Taiwan
Taichung Veterans General Hospital, Taichung, , Taiwan
Chang Gung Memorial Hospital, Taoyuan, , Taiwan
City Clinical Hospital #4, Dnipro, , Ukraine
Name: Naomi Schechter
Affiliation: Rakuten Medical
Role: STUDY_DIRECTOR